Oxford BioMedica PLC
OXOA
Company Profile
Business description
Oxford BioMedica PLC is a contract development and manufacturing organization (CDMO) focused on cell and gene therapy. The company specializes in viral vector development and manufacturing for cell and gene therapy, with expertise in lentivirus, adeno-associated virus (AAV), adenovirus, and other viral vector types. Geographically, it derives maximum revenue from the United States, and the rest from Europe, the UK, and the Rest of the world.
Contact
Transport Way
Windrush Court
OxfordOX4 6LT
GBRT: +44 1865783000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
986
Stocks News & Analysis
stocks
ASX major bank drives strong quarterly profit
Profit momentum remains robust yet shares overvalued.
stocks
Ask the analyst: What to expect in earnings season?
The key metrics that matter this earnings season.
stocks
ASX healthcare share remains undervalued ahead of earnings
Margin recovery remains the key driver for this ASX healthcare share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,063.80 | 36.20 | 0.40% |
| CAC 40 | 8,435.81 | 63.53 | 0.76% |
| DAX 40 | 25,447.82 | 348.82 | 1.39% |
| Dow JONES (US) | 52,239.94 | 292.69 | 0.56% |
| FTSE 100 | 10,817.21 | 80.98 | 0.75% |
| HKSE | 25,207.18 | 243.95 | 0.98% |
| NASDAQ | 24,947.45 | 28.38 | -0.11% |
| Nikkei 225 | 64,931.19 | 320.04 | 0.50% |
| NZX 50 Index | 13,850.69 | 78.40 | 0.57% |
| S&P 500 | 7,417.93 | 5.95 | 0.08% |
| S&P/ASX 200 | 8,894.00 | 36.10 | 0.41% |
| SSE Composite Index | 3,858.25 | 44.05 | 1.15% |